share_log

SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Armistice Capital, LLC(4.99%),Steven Boyd(4.99%)

SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Armistice Capital, LLC(4.99%),Steven Boyd(4.99%)

SC 13G/A：超过5%持股股东披露文件(修正)-Armistice Capital, LLC(4.99%),Steven Boyd(4.99%)
美股SEC公告 ·  2024/11/15 04:47

Moomoo AI 已提取核心信息

On September 30, 2024, Armistice Capital, LLC and Steven Boyd filed an amended Schedule 13G/A with the United States Securities and Exchange Commission, indicating a change in their holdings of Adial Pharmaceuticals, Inc. common stock. The filing revealed that both Armistice Capital and Boyd individually have shared voting and dispositive power over 336,310 shares of Adial Pharmaceuticals, which represents 4.99% of the company's class of common stock. The filing was made under Rule 13d-1(b), which applies to certain institutional investment managers. The shares are held by the Master Fund, which is managed by Armistice Capital, and Steven Boyd, as the managing member of Armistice Capital, may be deemed to beneficially own the securities held by the Master Fund. The Master Fund disclaims beneficial ownership of the securities due to its Investment Management Agreement with Armistice Capital. The filing also certifies that the securities were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of Adial Pharmaceuticals.
On September 30, 2024, Armistice Capital, LLC and Steven Boyd filed an amended Schedule 13G/A with the United States Securities and Exchange Commission, indicating a change in their holdings of Adial Pharmaceuticals, Inc. common stock. The filing revealed that both Armistice Capital and Boyd individually have shared voting and dispositive power over 336,310 shares of Adial Pharmaceuticals, which represents 4.99% of the company's class of common stock. The filing was made under Rule 13d-1(b), which applies to certain institutional investment managers. The shares are held by the Master Fund, which is managed by Armistice Capital, and Steven Boyd, as the managing member of Armistice Capital, may be deemed to beneficially own the securities held by the Master Fund. The Master Fund disclaims beneficial ownership of the securities due to its Investment Management Agreement with Armistice Capital. The filing also certifies that the securities were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of Adial Pharmaceuticals.
2024年9月30日，Armistice Capital, LLC和Steven Boyd向美国证券交易委员会提交了修订后的Schedule 13G/A，表明他们对Adial pharmaceuticals, Inc.普通股的持有量发生了变化。文件显示，Armistice Capital和Boyd各自对336,310股Adial pharmaceuticals的股份拥有共同的投票权和处置权，这代表了该公司普通股类别的4.99%。该文件是根据第13d-1(b)条规则提交的，适用于某些机构投资管理者。股份由Master Fund持有，Master Fund由Armistice Capital管理，...展开全部
2024年9月30日，Armistice Capital, LLC和Steven Boyd向美国证券交易委员会提交了修订后的Schedule 13G/A，表明他们对Adial pharmaceuticals, Inc.普通股的持有量发生了变化。文件显示，Armistice Capital和Boyd各自对336,310股Adial pharmaceuticals的股份拥有共同的投票权和处置权，这代表了该公司普通股类别的4.99%。该文件是根据第13d-1(b)条规则提交的，适用于某些机构投资管理者。股份由Master Fund持有，Master Fund由Armistice Capital管理，而作为Armistice Capital的管理成员，Steven Boyd可能被视为有权利拥有Master Fund持有的证券。由于与Armistice Capital的投资管理协议，Master Fund对所持证券不承认有利所有权。文件还证明，这些证券是在正常的业务过程中获得的，而不是为了改变或影响对Adial pharmaceuticals的控制。

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Organovo Holdings
    ONVO
    -- 1.270
    Silexion Therapeutics
    SLXN
    -- 1.230
    LAVA Therapeutics
    LVTX
    -- 1.340
    Dominari Holdings
    DOMH
    -- 9.900
    GT Biopharma
    GTBP
    -- 2.4600
    解锁完整榜单
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。
    热门讨论
    科技巨头财报季如火如荼，英伟达压轴会表现如何？
    星期四， $亚马逊 (AMZN.US)$ 股价在公司报告第四季度调整后每股收益为1.86美元，预估为每股1.50美元，营业收入为1877.9亿，预估为1873.2亿后下跌。该公司预测第一季度的营业收入数字低于华尔街的预期，预测本季度最多为1550亿，而分析师希望为1580亿。 星 展开
    亚马逊盈利预告：猜测开盘价，获取奖励！